Epac1 and lung scarring in idiopathic pulmonary fibrosis
Official title: Role of Epac1 in the Pathogenesis of Pulmonary Fibrosis
Funded at Icahn School of Medicine at Mount Sinai · NIH-11397242 · Data updated 2026-11-12
Looks at whether blocking a protein called Epac1 can reduce lung scarring in people with idiopathic pulmonary fibrosis.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | April 1, 2022 |
| Project end | March 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $422,500 |
| NIH project number | 5R01HL158998-05 |
| Project ID | NIH-11397242 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates would be people diagnosed with idiopathic pulmonary fibrosis who can provide lung tissue or cells or who may be eligible for future clinical testing of Epac1-targeting therapies.
✕Less likely to help
People without IPF or those with very advanced respiratory failure are unlikely to benefit directly from this preclinical-focused work.
What this research studies
If you have IPF, this project is looking at a protein called Epac1 that is higher in damaged lungs and lung cells from patients. Researchers will use patient lung tissue and cells, along with mouse models of lung fibrosis, to see how Epac1 drives scarring. They will test a drug called AM-001 that specifically blocks Epac1 in lab and animal experiments to see if scarring and harmful cell changes are reduced. The goal is to find whether Epac1 could become a new target for future treatments for people with IPF.
Why it matters
Potential benefit: If successful, this work could point to a new way to slow or reverse lung scarring in IPF and lead to future drug testing in patients.
How similar studies have gone: Targeting cAMP pathways has shown promise in lab studies, but selectively blocking Epac1 with AM-001 is a newer approach with preclinical support in heart models and limited testing so far in lung disease.
Where this research is happening
-
Icahn School of Medicine at Mount Sinai
New York, United States Active
Researchers
- Principal investigator: Hadri, Lahouaria — Icahn School of Medicine at Mount Sinai
- Study coordinator: Hadri, Lahouaria
Related research
Other NIH-funded projects on the same topics.
-
Molecular clues to progressive lung scarring
Researchers are studying how lung tissue becomes progressively scarred, focusing on cell signals and receptors that may drive fibrosis in people with lung disease.
-
Alveolar Cell Dysfunction in Pulmonary Fibrosis: Using SFTPC Mutations to Find New Targets
This grant explores how rare SFTPC mutations in alveolar cells may drive IPF and seeks new molecular targets to improve treatment.
-
Iron and scar-forming cells in the lungs (IPF)
Researchers are exploring how iron in the lungs may drive the scarring seen in idiopathic pulmonary fibrosis and whether this could lead to new therapies.
-
Repurposing Pyrvinium as an Inhaled Therapy for Idiopathic Pulmonary Fibrosis
A patient-friendly look at a project trying to use an existing drug, pyrvinium, as an inhaled treatment option for idiopathic pulmonary fibrosis (IPF).
-
Screening new compounds to reverse gene signatures in IPF lungs
A researcher hopes to find compounds that reverse harmful gene changes in the lungs of people with idiopathic pulmonary fibrosis (IPF).
-
Role of lactate transporters in lung scarring
Aims to see if blocking lactate transporters can slow or stop scar-forming cells from thickening the lungs in people with fibrotic lung disease.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.